arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Aligos Therapeutics, Inc.

ALGS
$5.57 ▲ +0.01 (+0.09%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
29 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Bearish
auto_awesome

Analytical Summary

Aligos Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $57.9M
Dividend Yield
Revenue Growth 810.0%
Op. Margin None
ROIC -85.9%
FCF / Share $-2.22
Trailing P/E
Price / Book 1.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

29-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.83M
↑ +810.0%
Net Income Profit after all expenses
$-23.04M
↓ -15.9%
FCF / Share Free cash flow per share
$-2.22
↑ +10.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
18
Cash Quality
93

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 29 quarters